Stradbio (co-founder & CEO is ex-CMO of Seagen) quietly picked up two Seagen-originated ADCs that $PFE ditched this year. Via @ApexOnco -> apexonco.com/node/2469/

$ONC BTK degrader updates. The company has toplined the pivotal portion of phase 1/2 Cadance-101 trial positive in r/r CLL, and is converting Cadance-302 from phase 3 to 2

An overlooked snippet in $BNTX's Q3 report yesterday - it's opted out of its 50/50 cost/profit share with $RHHBY on its neoantigen project autogene cevumeran: apexonco.com/biontech-shift…

$IDYA has confirmed it's decided to stop enrolment & close the phase 3 OptimUM-010 trial of darovasertib in neoadjuvant uveal melanoma. This study has looked in trouble for a while

apexonco.com/ideaya-shifts-…

$SNDX still hasn't started the Raven trial of Revuforj. I first spoke to the company about this study nearly a year ago, and it was posted on clinicaltrials.gov in May apexonco.com/syndaxs-raven-…

I should say that Raven is investigator-sponsored $SNDX

And now data from the phase 2 INCA34176-254 of Niktimvo + Jakafi in first-line GvHD are due in Q1 2027, from Q4 2026....back to the original timeline! $SNDX apexonco.com/niktimvos-firs…

$INCY has discontinued the Maestra-2 trial of its CDK2i INCB123667 in platinum-resistant ovarian cancer, to focus on front-line maintenance

Comparing $BMY's iza-bren Panku-Lung01 press release vs the adverse event slide in the #ESMO26 presentation. Serious TRAEs look pretty high

Good morning! If you're looking to catch up with what's been going on at #Esmo26 check out all the @ApexOnco stories from the weekend (some paywalled, others not) $MRNA $SMMT $AZN $AMGN $JNJ $TNGX $RVMD $HCM $CHRS $INCY $TAK $ZAI $IDYA $ELTX $GSK
apexonco.com/search/node?ke…

I've never seen this kind of wording together in a PR before:
"statistically significant, yet modest"
"higher rate of ILD"
"fatal events in a small proportion of patients"
$BNTX

PFS and OS results in Saffron trial of savolitinib + Tagrisso in post-Tagrisso EGFRm cMet-amplified/overexpressed NSCLC $AZN #ESMO26

And here's the KRAS inhibitor reimbursement picture, via Benjamin Besse #Esmo26

#Esmo26 discussant Benjamin Besse slams regulators for not permitting crossover in Krascendo-1 (gets applause). That's some endorsement!

Divarasib PFS & OS, vs approved KRAS G12C inhibitors in relapsed G12Cm NSCLC. Will this get a standing ovation?? #ESMO26 $RHHBY

Interesting tidbit from Krascendo-1 divarasib trial. In the control group, only 9% of pts got Krazati, "owing to limited drug availability worldwide" $RHHBY $AMGN $BMY #ESMO26

Discussant slide for Krascendo-1. Bye bye Lumakras & Krazati? $RHHBY $AMGN $BMY #SXMO26

Ivonescimab probably good enough for China approval in 1st-line choalgio. But it's underperformed on some metrics, and applicability to the west is limited. From #Esmo26, Harmoni-GI1 analysis via @ApexOnco -> apexonco.com/node/2442/ $SMMT $BNTX

Looks like $AZN ph3 has matched $IVBXF $TAK in Claudin18.2: Clarity-Gastric01 OS data look pretty similar to G-Hope-001 - but in a Western population. Also cites a 0.63 HR in ≥25 to <75% expressers. More at #Esmo26 presidential

Yikes! $PFE's failed ph3 study of integrin β6 ADC sigvotatug vedotin, Sigvie-002, in 2L+ NSCLC: no OS difference vs docetaxel, docetaxel did better in 3L+. Two more ph3 trials still ongoing! #Esmo26